Welcome to our dedicated page for Eli Lilly and news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly and stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Eli Lilly reported Q1 2023 revenue of $6.96 billion, down 11% year-over-year, primarily due to a significant decline in COVID-19 antibody sales. Excluding these revenues, the company saw a 10% increase, driven by strong performances from its growth products like Mounjaro, Trulicity, Verzenio, and Jardiance. Q1 2023 EPS decreased 29% to $1.49 on a reported basis and 38% to $1.62 on a non-GAAP basis. The company raised its 2023 EPS guidance, now forecasting reported EPS between $8.18 to $8.38, reflecting positive core business growth and successful pipeline advancements, including FDA approvals. Eli Lilly's new products contributed $573.6 million to revenue, with growth products revenue rising 18% to $4.56 billion.